Antitumor efficiency of D-α-tocopheryl polyethylene glycol 1000 succinate-b-poly(ε-caprolactone-ran-lactide) nanoparticle-based delivery of docetaxel in mice bearing cervical cancer

Journal of Biomedical Nanotechnology

Volumn 10, Issue 8, 2014, Pages 1509-1519

  Wang, Zhongyuan ^a   Wu, Yanping ^a   Zeng, Xiaowei ^a   Ma, Yaping ^b   Liu, Jian ^b   Tang, Xiaolong ^c   Gao, Yongfeng ^a   Liu, Kewei ^a   Zhang, Jinxie ^a   Ming, Pinghong ^a   Huang, Laiqiang ^a   Mei, Lin ^a  

^a TSINGHUA UNIVERSITY   (China)

^b Hybio Pharmaceutical Co Ltd   (China)

^c ANHUI UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Cancer chemotherapy; Drug delivery; Nanomedicine; Pharmaceutical nanotechnology

Indexed keywords

CHEMOTHERAPY; DISEASES; DRUG DELIVERY; DRUG PRODUCTS; MAMMALS; MEDICAL NANOTECHNOLOGY; NANOTECHNOLOGY; PARTICLE SIZE; POLYETHYLENE GLYCOLS; TUMORS;

CANCER CHEMOTHERAPY; CYTOTOXICITY IN VITRO; INHIBITION EFFECT; MORPHOLOGY AND SIZE; NANOPARTICLE FORMULATION; NANOPRECIPITATION METHOD; PARTICLE SIZE AND SURFACES; THERAPEUTIC EFFECTS;

NANOPARTICLES;

DOCETAXEL; MACROGOL; NANOPARTICLE; SUCCINIC ACID DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL VIABILITY; COMPARATIVE STUDY; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; CYTOTOXICITY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG DELIVERY SYSTEM; DRUG RELEASE; ENCAPSULATION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; MTT ASSAY; NONHUMAN; PARTICLE SIZE; SURFACE CHARGE; SURFACE PROPERTY; THERAPY EFFECT; UTERINE CERVIX CANCER; XENOGRAFT; ZETA POTENTIAL;

ALPHA-TOCOPHEROL; ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DRUG CARRIERS; FEMALE; HUMANS; MICE; NANOPARTICLES; POLYESTERS; POLYETHYLENE GLYCOLS; SUCCINATES; TAXOIDS; UTERINE CERVICAL NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84899699819     PISSN: 15507033     EISSN: 15507041     Source Type: Journal    
DOI: 10.1166/jbn.2014.1844     Document Type: Article

References (47)

1. J. Ferlay, H. R. Shin, F. Bray, D. Forman, C. Mathers, and D. M. Parkin, Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int. J. Cancer 127, 2893 (2010).
2. D. Khayat, E. C. Antoine, and D. Coeffic, Taxol in the management of cancers of the breast and the ovary. Cancer Invest. 18, 242 (2000).
3. K. N. Bhalla, Microtubule-targeted anticancer agents and apoptosis. Oncogene 22, 9075 (2003).
4. Y. Zhang, L. Tang, L. Sun, J. Bao, C. Song, L. Huang, K. Liu, Y. Tian, G. Tian, Z. Li, H. Sun, and L. Mei, A novel paclitaxel-loaded poly(epsilon- caprolactone)/poloxamer 188 blend nanoparticle overcoming multidrug resistance for cancer treatment. Acta Biomater. 6, 2045 (2010).
5. A. K. Singla, A. Garg, and D. Aggarwal, Paclitaxel and its formulations. Int. J. Pharm. 235, 179 (2002).
6. Z. Zhang, L. Mei, and S. S. Feng, Paclitaxel drug delivery systems. Expert. Opin. Drug Deliv. 10, 325 (2013).
7. Y. Wang, C. Wang, C. Gong, G. Guo, F. Luo, and Z. Qian, Polysorbate 80 coated poly(varepsilon-caprolactone)-poly(ethylene glycol)-poly(varepsilon- caprolactone) micelles for paclitaxel delivery. Int. J. Pharm. 434, 1 (2012).
8. C. Wang, J. Wang, T. Chen, Z. Luo, X. Yang, X. Pan, Y. Lin, Z. Qian, and X. Cai, Absorption, pharmacokinetics and disposition of biodegradable nanoscale preparations. Curr. Drug Metab. 13, 429 (2012).
9. J. Li, Z. He, S. Yu, S. Li, Q. Ma, Y. Yu, J. Zhang, R. Li, Y. Zheng, G. He, and X. Song, Micelles based on methoxy poly(ethylene glycol)-cholesterol conjugate for controlled and targeted drug delivery of a poorly water soluble drug. J. Biomed. Nanotechnol. 8, 809 (2012).
10. J. Liao, C. Wang, Y. Wang, F. Luo, and Z. Qian, Recent advances in formation, properties, and applications of polymersomes. Curr. Pharm. Des. 18, 3432 (2012).
11. B. Xue, Y. Wang, X. Tang, P. Xie, F. Luo, C. Wu, and Z. Qian, Biodegradable self-assembled MPEG-PCL micelles for hydrophobic oridonin delivery in vitro. J. Biomed. Nanotechnol. 8, 80 (2012).
12. Z. Zhang, S. H. Lee, C. W. Gan, and S. S. Feng, In vitro and in vivo investigation on PLA-TPGS nanoparticles for controlled and sustained small molecule chemotherapy. Pharm. Res. 25, 1925 (2008).
13. M. Vert, Degradable and bioresorbable polymers in surgery and in pharmacology: Beliefs and facts. J. Mater. Sci. Mater. Med. 20, 437 (2009).
14. L. Huang, H. Chen, Y. Zheng, X. Song, R. Liu, K. Liu, X. Zeng, and L. Mei, Nanoformulation of D-alpha-tocopheryl polyethylene glycol 1000 succinate-b-poly(epsilon-caprolactone-ran-glycolide) diblock copolymer for breast cancer therapy. Integr. Biol. (Camb.) 3, 993 (2011).
15. F. Yan, C. Zhang, Y. Zheng, L. Mei, L. Tang, C. Song, H. Sun, and L. Huang, The effect of poloxamer 188 on nanoparticle morphology, size, cancer cell uptake, and cytotoxicity. Nanomedicine 6, 170 (2010).
16. Y. Wang, C. Wang, F. Luo, X. Yan, and Z. Qian, Micelles of methoxy poly(ethylene glycol)-poly(epsilon-caprolactone) as a novel drug delivery vehicle for tacrolimus. J. Biomed. Nanotechnol. 9, 147 (2013).
17. H. Sun, L. Mei, C. Song, X. Cui, and P. Wang, The in vivo degradation, absorption and excretion of PCL-based implant. Biomaterials 27, 1735 (2006).
18. Y. Ma, Y. Zheng, K. Liu, G. Tian, Y. Tian, L. Xu, F. Yan, L. Huang, and L. Mei, Nanoparticles of poly(lactide-co-glycolide)-d-a-tocopheryl polyethylene glycol 1000 succinate random copolymer for cancer treatment. Nanoscale Res. Lett. 5, 1161 (2010).
19. S. Shi, X. Zhu, Q. Guo, Y. Wang, T. Zuo, F. Luo, and Z. Qian, Self-assembled mPEG-PCL-g-PEI micelles for simultaneous codelivery of chemotherapeutic drugs and DNA: Synthesis and characterization in vitro. Int. J. Nanomedicine 7, 1749 (2012).
20. C. Gong, S. Deng, Q. Wu, M. Xiang, X. Wei, L. Li, X. Gao, B. Wang, L. Sun, Y. Chen, Y. Li, L. Liu, Z. Qian, and Y. Wei, Improving antiangiogenesis and anti-tumor activity of curcumin by biodegradable polymeric micelles. Biomaterials 34, 1413 (2013).
21. C. C. Chen, J. Y. Chueh, H. Tseng, H. M. Huang, and S. Y. Lee, Preparation and characterization of biodegradable PLA polymeric blends. Biomaterials 24, 1167 (2003).
22. A. P. Gupta and V. Kumar, New emerging trends in synthetic biodegradable polymers - Polylactide: A critique. Eur. Polym. J. 43, 4053 (2007).
23. S. B. Zhou, J. G. Xu, H. Yang, and X. M. Deng, Synthesis and characterization of biodegradable poly(epsilon-caprolactone)-polyglycolide- poly(ethylene glycol) monomethyl ether random copolymer. Macromolecular Materials and Engineering 289, 576 (2004).
24. Y. D. Ma, L. Q. Huang, C. X. Song, X. W. Zeng, G. Liu, and L. Mei, Nanoparticle formulation of poly(epsilon-caprolactone-co-lactide)-D-alpha- tocopheryl polyethylene glycol 1000 succinate random copolymer for cervical cancer treatment. Polymer 51, 5952 (2010).
25. Z. Zhang, X. Yang, and S. S. Feng, Copolymer technology for advanced nanomedicine. Nanomedicine (Lond.) 6, 583 (2011).
26. L. Mu and S. S. Feng, Vitamin E TPGS used as emulsifier in the solvent evaporation/extraction technique for fabrication of polymeric nanospheres for controlled release of paclitaxel (Taxol). J. Control. Release 80, 129 (2002).
27. L. Mu and S. S. Feng, A novel controlled release formulation for the anticancer drug paclitaxel (Taxol): PLGA nanoparticles containing vitamin E TPGS. J. Control. Release 86, 33 (2003).
28. L. Zhao, Y. Shi, S. Zou, M. Sun, L. Lil, and G. Zhail, Formulation and in vitro evaluation of quercetin loaded polymeric micelles composed of pluronic P123 and D-a-tocopheryl polyethylene glycol succinate. J. Biomed. Nanotechnol. 7, 358 (2011).
29. Z. Zhang, S. Tan, and S. S. Feng, Vitamin E TPGS as a molecular biomaterial for drug delivery. Biomaterials 33, 4889 (2012).
30. Y. Guo, J. Luo, S. Tan, B. O. Otieno, and Z. Zhang, The applications of Vitamin E TPGS in drug delivery. Eur. J. Pharm. Sci. 49, 175 (2013).
31. K. Y. Win and S. S. Feng, Effects of particle size and surface coating on cellular uptake of polymeric nanoparticles for oral delivery of anticancer drugs. Biomaterials 26, 2713 (2005).
32. K. Y. Win and S. S. Feng, In vitro and in vivo studies on vitamin E TPGS-emulsified poly(D,L-lactic-co-glycolic acid) nanoparticles for paclitaxel formulation. Biomaterials 27, 2285 (2006).
33. E. M. Collnot, C. Baldes, M. F. Wempe, R. Kappl, J. Huttermann, J. A. Hyatt, K. J. Edgar, U. F. Schaefer, and C. M. Lehr, Mechanism of inhibition of P-glycoprotein mediated efflux by vitamin E TPGS: Influence on ATPase activity and membrane fluidity. Mol. Pharm. 4, 465 (2007).
34. J. M. Dintaman and J. A. Silverman, Inhibition of P-glycoprotein by D-alpha-tocopheryl polyethylene glycol 1000 succinate (TPGS). Pharm. Res. 16, 1550 (1999).
35. S. Zhao, S. Tan, Y. Guo, J. Huang, M. Chu, H. Liu, and Z. Zhang, pH-sensitive docetaxel-loaded d-alpha-tocopheryl polyethylene glycol succinate-poly(beta-amino ester) copolymer nanoparticles for overcoming multidrug resistance. Biomacromolecules 14, 2636 (2013).
36. L. Yu, A. Bridgers, J. Polli, A. Vickers, S. Long, A. Roy, R. Winnike, and M. Coffin, Vitamin E-TPGS increases absorption flux of an HIV protease inhibitor by enhancing its solubility and permeability. Pharm. Res. 16, 1812 (1999).
37. P. M. Valencia, M. H. Hanewich-Hollatz, W. Gao, F. Karim, R. Langer, R. Karnik, and O. C. Farokhzad, Effects of ligands with different water solubilities on self-assembly and properties of targeted nanoparticles. Biomaterials 32, 6226 (2011).
38. X. Zeng, W. Tao, L. Mei, L. Huang, C. Tan, and S. S. Feng, Cholic acid-functionalized nanoparticles of star-shaped PLGA-vitamin E TPGS copolymer for docetaxel delivery to cervical cancer. Biomaterials 34, 6058 (2013).
39. S. S. Feng, L. Mei, P. Anitha, C. W. Gan, and W. Zhou, Poly(lactide)-vitamin E derivative/montmorillonite nanoparticle formulations for the oral delivery of docetaxel. Biomaterials 30, 3297 (2009).
40. J. Tomasina, S. Lheureux, P. Gauduchon, S. Rault, and A. Malzert-Freon, Nanocarriers for the targeted treatment of ovarian cancers. Biomaterials 34, 1073 (2013).
41. S. Acharya and S. K. Sahoo, PLGA nanoparticles containing various anticancer agents and tumour delivery by EPR effect. Adv. Drug Deliv. Rev. 63, 170 (2011).
42. Y. Dong and S. S. Feng, Methoxy poly(ethylene glycol)-poly(lactide) (MPEG-PLA) nanoparticles for controlled delivery of anticancer drugs. Biomaterials 25, 2843 (2004).
43. B. C. Hancock and M. Parks, What is the true solubility advantage for amorphous pharmaceuticals? Pharm. Res. 17, 397 (2000).
44. P. Gupta, G. Chawla, and A. K. Bansal, Physical stability and solubility advantage from amorphous celecoxib: The role of thermodynamic quantities and molecular mobility. Mol. Pharm. 1, 406 (2004).
45. J. Davda and V. Labhasetwar, Characterization of nanoparticle uptake by endothelial cells. Int. J. Pharm. 233, 51 (2002).
46. M. G. Qaddoumi, H. Ueda, J. Yang, J. Davda, V. Labhasetwar, and V. H. Lee, The characteristics and mechanisms of uptake of PLGA nanoparticles in rabbit conjunctival epithelial cell layers. Pharm. Res. 21, 641 (2004).
47. J. Rejman, V. Oberle, I. S. Zuhorn, and D. Hoekstra, Size-dependent internalization of particles via the pathways of clathrinand caveolae-mediated endocytosis. Biochem. J. 377, 159 (2004).